chlorphenamine ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
616 132-22-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • chlorphenamine
  • chloropheniramine
  • chlorophenylpyridamine
  • chloroprophenpyridamine
  • chlorpheniramine
  • chlorprophenpyridamine
  • chlorpheniramine maleate
  • chlorpheniramine tannate
  • chlorpheniramine polistirex
A histamine H1 antagonist used in allergic reactions, hay fever, rhinitis, urticaria, and asthma. It has also been used in veterinary applications. One of the most widely used of the classical antihistaminics, it generally causes less drowsiness and sedation than PROMETHAZINE.
  • Molecular weight: 274.79
  • Formula: C16H19ClN2
  • CLOGP: 3.15
  • LIPINSKI: 0
  • HAC: 2
  • HDO: 0
  • TPSA: 16.13
  • ALOGS: -3.72
  • ROTB: 5

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
12 mg O
12 mg P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 10 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.48 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 41 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 3.30 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 2.50 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.70 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 22 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Aug. 15, 1950 FDA BAYER HEALTHCARE LLC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug ineffective 164.57 10.31 460 58934 818873 49726857
Contraindicated product administered 152.30 10.31 5 59389 148953 50396777
Synovitis 111.50 10.31 9 59385 123856 50421874
Drug intolerance 110.17 10.31 60 59334 219044 50326686
Sinusitis 103.26 10.31 435 58959 170123 50375607
Dyspnoea 103.13 10.31 1037 58357 546571 49999159
Glossodynia 94.67 10.31 12 59382 115557 50430173
Chest discomfort 89.92 10.31 276 59118 92446 50453284
Maternal exposure during pregnancy 85.91 10.31 40 59354 159738 50385992
Systemic lupus erythematosus 85.77 10.31 29 59365 140593 50405137
Asthma 83.00 10.31 262 59132 89075 50456655
Treatment failure 82.88 10.31 29 59365 137608 50408122
Joint swelling 78.28 10.31 104 59290 245182 50300548
Therapeutic product effect decreased 76.38 10.31 32 59362 136018 50409712
Pericarditis 75.86 10.31 4 59390 78685 50467045
Arthropathy 61.26 10.31 57 59337 157849 50387881
Cough 61.13 10.31 488 58906 240776 50304954
Rheumatoid arthritis 59.53 10.31 91 59303 202459 50343271
Hepatic enzyme increased 58.92 10.31 45 59349 137335 50408395
Completed suicide 58.12 10.31 42 59352 131847 50413883
Wound 57.60 10.31 26 59368 105768 50439962
General physical health deterioration 55.74 10.31 51 59343 142383 50403347
Anaphylactic reaction 53.39 10.31 162 59232 53893 50491837
Neuropathy peripheral 51.06 10.31 237 59157 96520 50449210
Chest pain 49.91 10.31 367 59027 176515 50369215
Rheumatoid factor positive 46.63 10.31 3 59391 49856 50495874
Neutropenic sepsis 45.92 10.31 69 59325 14078 50531652
Discomfort 45.83 10.31 36 59358 108344 50437386
Toxicity to various agents 44.00 10.31 117 59277 212382 50333348
Eosinophilic colitis 43.10 10.31 13 59381 137 50545593
Infective pulmonary exacerbation of cystic fibrosis 41.82 10.31 49 59345 7860 50537870
Anxiety 41.58 10.31 353 59041 177253 50368477
Diarrhoea 41.55 10.31 942 58452 587534 49958196
Helicobacter infection 41.07 10.31 5 59389 49697 50496033
Flushing 39.75 10.31 170 59224 66845 50478885
Excessive eye blinking 36.07 10.31 19 59375 927 50544803
Drug interaction 34.79 10.31 119 59275 199502 50346228
Upper respiratory tract infection 34.44 10.31 161 59233 65737 50479993
Headache 33.89 10.31 805 58589 505730 50040000
Ejection fraction decreased 32.46 10.31 69 59325 18451 50527279
Swelling face 31.63 10.31 134 59260 52461 50493269
Pneumonia 31.57 10.31 621 58773 377780 50167950
Rhinitis allergic 30.65 10.31 40 59354 7160 50538570
Wheezing 30.54 10.31 149 59245 61898 50483832
Product quality issue 30.01 10.31 92 59302 30766 50514964
Back pain 29.58 10.31 391 59003 219639 50326091
Bronchitis 29.27 10.31 216 59178 103943 50441787
Pulmonary embolism 29.21 10.31 212 59182 101492 50444238
Palpitations 28.89 10.31 200 59194 94306 50451424
Sinusitis fungal 27.87 10.31 18 59376 1288 50544442
Dilatation intrahepatic duct acquired 27.60 10.31 14 59380 631 50545099
Product use issue 27.48 10.31 87 59307 149388 50396342
Nasal congestion 26.78 10.31 125 59269 50995 50494735
Dizziness 26.74 10.31 562 58832 345807 50199923
Deep vein thrombosis 26.60 10.31 162 59232 73142 50472588
Emotional distress 26.53 10.31 84 59310 28579 50517151
Chronic sinusitis 25.94 10.31 34 59360 6111 50539619
Folliculitis 25.87 10.31 7 59387 39218 50506512
Bronchospasm 25.64 10.31 55 59339 14799 50530931
Musculoskeletal stiffness 25.62 10.31 72 59322 128409 50417321
Swelling 25.58 10.31 135 59259 200737 50344993
Chronic obstructive pulmonary disease 25.36 10.31 127 59267 53308 50492422
Gastrooesophageal reflux disease 25.31 10.31 165 59229 76263 50469467
Abdominal discomfort 25.07 10.31 164 59230 231477 50314253
Nausea 25.03 10.31 1038 58356 704360 49841370
Sleep apnoea syndrome 24.95 10.31 73 59321 23795 50521935
Sputum increased 24.23 10.31 19 59375 1848 50543882
Salpingo-oophorectomy unilateral 23.91 10.31 12 59382 529 50545201
Anosmia 23.57 10.31 26 59368 3905 50541825
Lip swelling 23.36 10.31 73 59321 24663 50521067
Nail infection 23.24 10.31 19 59375 1962 50543768
Nasal polyps 22.88 10.31 21 59373 2533 50543197
Oropharyngeal pain 22.23 10.31 162 59232 77639 50468091
Off label use 21.82 10.31 409 58985 474017 50071713
Diverticulum 21.51 10.31 42 59352 10572 50535158
Tonsillar hypertrophy 21.15 10.31 13 59381 853 50544877
Injury 20.94 10.31 113 59281 48812 50496918
Gallbladder polyp 20.67 10.31 12 59382 709 50545021
Malignant neoplasm progression 20.57 10.31 30 59364 68094 50477636
Hepatocellular injury 20.51 10.31 3 59391 25944 50519786
Condition aggravated 20.27 10.31 237 59157 296821 50248909
Poor quality device used 20.15 10.31 17 59377 1834 50543896
Foetal exposure during pregnancy 19.79 10.31 4 59390 27355 50518375
Swollen tongue 19.64 10.31 76 59318 28554 50517176
Abdominal pain 19.42 10.31 387 59007 235841 50309889
Rhinorrhoea 19.35 10.31 115 59279 51468 50494262
Coma 19.27 10.31 23 59371 56856 50488874
Throat tightness 19.20 10.31 61 59333 20786 50524944
Candida infection 19.14 10.31 66 59328 23457 50522273
Chemical burns of eye 19.11 10.31 6 59388 73 50545657
Muscle spasms 18.93 10.31 228 59166 125325 50420405
Impaired healing 18.93 10.31 33 59361 69753 50475977
Sinus disorder 18.86 10.31 56 59338 18402 50527328
Biliary sepsis 18.85 10.31 12 59382 838 50544892
Arthralgia 18.41 10.31 384 59010 438318 50107412
Victim of chemical submission 18.35 10.31 8 59386 255 50545475
Infusion site erythema 18.26 10.31 35 59359 8692 50537038
Urinary tract infection 18.07 10.31 366 59028 223654 50322076
Red blood cell sedimentation rate increased 18.03 10.31 6 59388 29410 50516320
Therapeutic product effect incomplete 17.71 10.31 52 59342 91463 50454267
Constipation 17.59 10.31 311 59083 185397 50360333
Acute kidney injury 17.53 10.31 177 59217 227881 50317849
Migraine 17.25 10.31 149 59245 75131 50470599
Acute sinusitis 17.09 10.31 21 59373 3539 50542191
Urticaria 16.87 10.31 229 59165 129332 50416398
Hypoxia 16.69 10.31 110 59284 51013 50494717
Diffuse large B-cell lymphoma refractory 16.59 10.31 12 59382 1034 50544696
Infusion site nodule 15.79 10.31 12 59382 1115 50544615
Mobility decreased 15.79 10.31 45 59349 79903 50465827
Hyperkalaemia 15.70 10.31 20 59374 48069 50497661
Erythema 15.62 10.31 250 59144 146164 50399566
Nasal discomfort 15.55 10.31 21 59373 3883 50541847
Administration site extravasation 15.54 10.31 10 59384 711 50545019
Ear infection 15.48 10.31 66 59328 25904 50519826
Drug reaction with eosinophilia and systemic symptoms 15.44 10.31 7 59387 28417 50517313
Pain in jaw 15.27 10.31 87 59307 38341 50507389
Retinal detachment 15.22 10.31 24 59370 5105 50540625
Death 15.08 10.31 280 59114 325099 50220631
Acute respiratory failure 14.79 10.31 70 59324 28712 50517018
Laryngospasm 14.79 10.31 17 59377 2671 50543059
Cholecystitis chronic 14.66 10.31 34 59360 9635 50536095
Panic attack 14.65 10.31 53 59341 19289 50526441
Exposure during pregnancy 14.47 10.31 83 59311 120932 50424798
Acute interstitial pneumonitis 14.32 10.31 9 59385 614 50545116
Genital ulceration 14.22 10.31 8 59386 445 50545285
Premature delivery 14.20 10.31 5 59389 23658 50522072
Sopor 14.18 10.31 3 59391 19876 50525854
Blister 14.14 10.31 52 59342 85366 50460364
Prosopagnosia 14.14 10.31 4 59390 33 50545697
Agranulocytosis 13.79 10.31 4 59390 21417 50524313
Haemodialysis complication 13.60 10.31 6 59388 197 50545533
Blood creatinine increased 13.52 10.31 45 59349 76115 50469615
Mucosal inflammation 13.49 10.31 87 59307 40055 50505675
C-reactive protein increased 13.43 10.31 37 59357 66437 50479293
Delirium 13.41 10.31 15 59379 38177 50507553
Depression 13.24 10.31 270 59124 165153 50380577
Vulvovaginal candidiasis 13.12 10.31 16 59378 2676 50543054
Multiple allergies 13.10 10.31 30 59364 8433 50537297
Product dose omission issue 13.09 10.31 295 59099 183543 50362187
Eosinophilic myocarditis 12.98 10.31 7 59387 358 50545372
Hereditary angioedema 12.86 10.31 23 59371 5419 50540311
Ventricular extrasystoles 12.80 10.31 34 59360 10482 50535248
Feeling hot 12.59 10.31 84 59310 39118 50506612
Pain 12.50 10.31 554 58840 578349 49967381
Lacrimation increased 12.39 10.31 46 59348 16946 50528784
Gastroenteritis viral 12.19 10.31 49 59345 18737 50526993
Nail dystrophy 12.17 10.31 9 59385 802 50544928
Biliary dyskinesia 12.17 10.31 15 59379 2535 50543195
Pancreatitis chronic 12.15 10.31 14 59380 2206 50543524
Terminal ileitis 12.01 10.31 8 59386 603 50545127
Diastolic dysfunction 12.01 10.31 22 59372 5280 50540450
Renal failure 11.77 10.31 75 59319 106558 50439172
Hip arthroplasty 11.77 10.31 11 59383 30418 50515312
Multiple organ dysfunction syndrome 11.75 10.31 26 59368 50311 50495419
Pyrexia 11.74 10.31 552 58842 379651 50166079
Infusion site swelling 11.73 10.31 26 59368 7150 50538580
Ageusia 11.70 10.31 35 59359 11548 50534182
Irritable bowel syndrome 11.66 10.31 27 59367 51414 50494316
Tongue pruritus 11.65 10.31 7 59387 441 50545289
Product prescribing error 11.64 10.31 5 59389 20956 50524774
Haemoptysis 11.58 10.31 60 59334 25513 50520217
Drug resistance 11.42 10.31 4 59390 18985 50526745
Hiatus hernia 11.23 10.31 47 59347 18297 50527433
Gastrointestinal disorder 11.18 10.31 65 59329 94391 50451339
HER2 positive breast cancer 11.16 10.31 6 59388 305 50545425
Hepatic failure 10.99 10.31 13 59381 32270 50513460
Low turnover osteopathy 10.91 10.31 18 59376 3976 50541754
Dyspnoea at rest 10.73 10.31 17 59377 3630 50542100
Loss of personal independence in daily activities 10.72 10.31 44 59350 70006 50475724
Embolism venous 10.70 10.31 14 59380 2511 50543219
Alopecia 10.69 10.31 213 59181 244834 50300896
Female genital tract fistula 10.66 10.31 17 59377 3649 50542081
Interstitial lung disease 10.44 10.31 30 59364 53146 50492584
Axillary pain 10.42 10.31 11 59383 1573 50544157
Retching 10.39 10.31 36 59358 12826 50532904
Coronary artery disease 10.34 10.31 65 59329 29661 50516069
Gallbladder disorder 10.33 10.31 43 59351 16699 50529031

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Sinusitis 63.87 11.23 118 28840 34232 29511337
Lower respiratory tract infection 51.74 11.23 93 28865 26409 29519160
Asthma 42.55 11.23 99 28859 33750 29511819
Painful respiration 41.17 11.23 21 28937 1153 29544416
Upper respiratory tract infection 40.02 11.23 85 28873 27264 29518305
Chest injury 39.96 11.23 22 28936 1411 29544158
Infective pulmonary exacerbation of cystic fibrosis 37.60 11.23 38 28920 6198 29539371
Infusion related reaction 37.39 11.23 111 28847 43775 29501794
Walking aid user 36.64 11.23 21 28937 1456 29544113
General physical health deterioration 34.47 11.23 30 28928 102827 29442742
Dry skin 31.32 11.23 70 28888 23237 29522332
Dyspnoea 31.11 11.23 470 28488 326262 29219307
Drug ineffective 30.77 11.23 219 28739 362951 29182618
Urticaria 30.49 11.23 120 28838 54540 29491029
Bronchitis 30.22 11.23 92 28866 36776 29508793
Cough 28.52 11.23 217 28741 126510 29419059
Flushing 27.27 11.23 76 28882 28916 29516653
Hypoacusis 26.10 11.23 49 28909 14374 29531195
Toxic epidermal necrolysis 26.06 11.23 56 28902 18097 29527472
Feeling cold 25.75 11.23 38 28920 9153 29536416
Failure to anastomose 25.01 11.23 9 28949 206 29545363
Neutropenic sepsis 23.97 11.23 42 28916 11685 29533884
Oropharyngeal blistering 22.66 11.23 8 28950 173 29545396
Hypersomnia 22.61 11.23 39 28919 10715 29534854
Rash 22.01 11.23 283 28675 189536 29356033
Pruritus 21.91 11.23 192 28766 116657 29428912
Lip swelling 21.03 11.23 41 28917 12369 29533200
Personality change 20.50 11.23 24 28934 4614 29540955
Pneumonia 20.26 11.23 432 28526 319740 29225829
Febrile neutropenia 19.80 11.23 182 28776 112058 29433511
Seasonal allergy 18.67 11.23 24 28934 5078 29540491
Nasal congestion 18.26 11.23 50 28908 18829 29526740
Hot flush 18.14 11.23 43 28915 14827 29530742
Oral candidiasis 17.65 11.23 35 28923 10687 29534882
Lactic acidosis 17.62 11.23 4 28954 30243 29515326
Hypoxic-ischaemic encephalopathy 17.02 11.23 21 28937 4263 29541306
Productive cough 16.91 11.23 68 28890 31191 29514378
Cystic fibrosis 16.88 11.23 13 28945 1479 29544090
Chest discomfort 16.71 11.23 89 28869 45894 29499675
Peripheral swelling 16.54 11.23 113 28845 63626 29481943
Off label use 16.50 11.23 202 28756 300598 29244971
Acute kidney injury 16.16 11.23 174 28784 265093 29280476
Malignant neoplasm progression 15.95 11.23 30 28928 73829 29471740
Sputum increased 15.95 11.23 14 28944 1913 29543656
Renal failure 15.91 11.23 61 28897 118538 29427031
HIV associated nephropathy 15.54 11.23 7 28951 291 29545278
Constipation 15.29 11.23 175 28783 113985 29431584
Aortic aneurysm 15.01 11.23 24 28934 6196 29539373
Treatment failure 14.66 11.23 9 28949 36930 29508639
Hypersensitivity 14.45 11.23 95 28863 52808 29492761
Drug hypersensitivity 14.18 11.23 115 28843 68291 29477278
Wheezing 13.94 11.23 67 28891 33173 29512396
Rhinitis allergic 13.78 11.23 15 28943 2665 29542904
Accidental exposure to product by child 13.60 11.23 11 28947 1343 29544226
Lip dry 13.31 11.23 10 28948 1096 29544473
Swelling face 13.27 11.23 47 28911 20303 29525266
Death 13.16 11.23 246 28712 341838 29203731
Drug interaction 13.02 11.23 127 28831 197258 29348311
Rhabdomyolysis 12.87 11.23 25 28933 60783 29484786
Limb mass 12.84 11.23 8 28950 646 29544923
Sputum discoloured 12.76 11.23 23 28935 6540 29539029
Chills 12.75 11.23 116 28842 71184 29474385
Infusion site pain 12.70 11.23 15 28943 2910 29542659
Hyperkalaemia 12.34 11.23 26 28932 61366 29484203
Pyrexia 11.93 11.23 367 28591 287255 29258314
Blood creatinine increased 11.91 11.23 43 28915 85059 29460510
Neutropenic infection 11.84 11.23 10 28948 1297 29544272
Bradycardia foetal 11.54 11.23 6 28952 343 29545226
Fatigue 11.53 11.23 398 28560 316423 29229146
Dyspnoea exertional 11.51 11.23 68 28890 36422 29509147
Therapeutic product effect incomplete 11.39 11.23 13 28945 39292 29506277

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug ineffective 141.67 9.94 468 70850 839779 63587635
Dyspnoea 115.60 9.94 1257 70061 717417 63709997
Contraindicated product administered 98.46 9.94 5 71313 107824 64319590
Chest discomfort 91.02 9.94 309 71009 115797 64311617
Synovitis 78.14 9.94 9 71309 99081 64328333
General physical health deterioration 75.34 9.94 69 71249 204356 64223058
Asthma 75.12 9.94 254 71064 94971 64332443
Infective pulmonary exacerbation of cystic fibrosis 74.57 9.94 78 71240 11718 64415696
Cough 69.53 9.94 571 70747 301577 64125837
Neutropenic sepsis 65.63 9.94 103 71215 23169 64404245
Drug intolerance 64.02 9.94 68 71250 187924 64239490
Flushing 59.58 9.94 207 71111 78441 64348973
Treatment failure 58.43 9.94 28 71290 116788 64310626
Joint swelling 53.27 9.94 98 71220 215284 64212130
Drug interaction 52.56 9.94 214 71104 361869 64065545
Pemphigus 51.87 9.94 4 71314 60697 64366717
Sinusitis 50.06 9.94 304 71014 145624 64281790
Pericarditis 48.49 9.94 6 71312 62510 64364904
Anaphylactic reaction 47.97 9.94 176 71142 68488 64358926
Upper respiratory tract infection 45.44 9.94 180 71138 72605 64354809
Chest pain 45.43 9.94 429 70889 235551 64191863
Swelling face 45.04 9.94 156 71162 59010 64368404
Acute kidney injury 43.73 9.94 304 71014 448936 63978478
Lip swelling 42.67 9.94 103 71215 31804 64395610
Anxiety 42.34 9.94 375 70943 202274 64225140
Neuropathy peripheral 41.04 9.94 246 71072 117279 64310135
Rheumatoid arthritis 40.39 9.94 75 71243 164219 64263195
Pneumonia 39.04 9.94 850 70468 558726 63868688
Therapeutic product effect decreased 38.94 9.94 42 71276 115309 64312105
Sputum increased 38.41 9.94 32 71286 3603 64423811
Completed suicide 38.23 9.94 124 71194 224290 64203124
Maternal exposure during pregnancy 38.19 9.94 30 71288 95854 64331560
Pulmonary embolism 37.10 9.94 283 71035 146073 64281341
Systemic lupus erythematosus 36.72 9.94 20 71298 77592 64349822
Wheezing 35.03 9.94 179 71139 80400 64347014
Palpitations 34.76 9.94 216 71102 104272 64323142
Product quality issue 32.41 9.94 89 71229 29710 64397704
Constipation 32.03 9.94 391 70927 228946 64198468
Rhinitis allergic 31.96 9.94 42 71276 8036 64419378
Helicobacter infection 31.48 9.94 3 71315 38359 64389055
Urticaria 31.47 9.94 274 71044 147043 64280371
Nasal congestion 31.36 9.94 140 71178 59518 64367896
Eosinophilic colitis 31.30 9.94 13 71305 390 64427024
Hyperkalaemia 30.74 9.94 40 71278 101089 64326325
Gastrooesophageal reflux disease 30.28 9.94 176 71142 82967 64344447
Malignant neoplasm progression 30.03 9.94 49 71269 112822 64314592
Renal failure 29.83 9.94 102 71216 181586 64245828
Hepatic enzyme increased 29.62 9.94 62 71256 129881 64297533
Excessive eye blinking 29.45 9.94 18 71300 1242 64426172
Chest injury 29.05 9.94 23 71295 2410 64425004
Glossodynia 28.72 9.94 18 71300 64678 64362736
Off label use 28.68 9.94 510 70808 632296 63795118
Back pain 28.48 9.94 411 70907 249760 64177654
Rheumatoid factor positive 27.97 9.94 3 71315 34935 64392479
Bronchospasm 27.93 9.94 69 71249 21613 64405801
Sleep apnoea syndrome 27.52 9.94 84 71234 29748 64397666
Lower respiratory tract infection 26.86 9.94 188 71130 94426 64332988
Deep vein thrombosis 26.43 9.94 203 71115 104979 64322435
Febrile neutropenia 25.78 9.94 319 70999 187338 64240076
Drug resistance 25.73 9.94 4 71314 35098 64392316
Arthropathy 25.69 9.94 60 71258 120907 64306507
Plethoric face 25.63 9.94 6 71312 22 64427392
Salpingo-oophorectomy unilateral 25.58 9.94 12 71306 484 64426930
Blood creatinine increased 25.27 9.94 72 71246 135710 64291704
Headache 25.04 9.94 764 70554 528703 63898711
Lactic acidosis 24.72 9.94 19 71299 61391 64366023
Dilatation intrahepatic duct acquired 24.56 9.94 13 71305 681 64426733
Sinusitis fungal 24.49 9.94 18 71300 1688 64425726
Lacrimation increased 24.29 9.94 59 71259 18287 64409127
Emotional distress 24.01 9.94 91 71227 35947 64391467
Interstitial lung disease 23.67 9.94 45 71273 97687 64329727
Sopor 22.63 9.94 3 71315 29658 64397756
Bronchitis 22.56 9.94 201 71117 108542 64318872
Diarrhoea 22.31 9.94 994 70324 721710 63705704
Therapeutic product effect incomplete 22.24 9.94 51 71267 103431 64323983
Hypoxia 22.07 9.94 170 71148 87979 64339435
Oropharyngeal pain 22.04 9.94 171 71147 88696 64338718
C-reactive protein increased 21.87 9.94 45 71273 94864 64332550
Dizziness 21.75 9.94 626 70692 429537 63997877
Dry skin 21.09 9.94 112 71206 51049 64376365
Painful respiration 20.60 9.94 21 71297 3060 64424354
Migraine 20.48 9.94 129 71189 62548 64364866
Ejection fraction decreased 20.39 9.94 74 71244 28633 64398781
Multiple organ dysfunction syndrome 20.20 9.94 52 71266 101361 64326053
Pyrexia 20.09 9.94 781 70537 557863 63869551
Injury 20.04 9.94 118 71200 55874 64371540
Coma 19.80 9.94 42 71276 87573 64339841
Failure to anastomose 19.64 9.94 8 71310 228 64427186
Hypersomnia 19.59 9.94 57 71261 19660 64407754
Tachycardia 19.56 9.94 252 71066 149327 64278087
Nasal polyps 19.45 9.94 22 71296 3607 64423807
Chronic sinusitis 19.36 9.94 29 71289 6263 64421151
Musculoskeletal stiffness 18.99 9.94 71 71247 123135 64304279
Nail infection 18.98 9.94 16 71302 1831 64425583
Hepatic failure 18.88 9.94 20 71298 55374 64372040
Erythema 18.82 9.94 301 71017 186769 64240645
Nausea 18.70 9.94 1054 70264 784746 63642668
Acute sinusitis 18.59 9.94 23 71295 4143 64423271
Throat tightness 18.44 9.94 62 71256 23098 64404316
Delirium 18.44 9.94 30 71288 69164 64358250
Oral candidiasis 18.36 9.94 62 71256 23150 64404264
Chronic obstructive pulmonary disease 18.33 9.94 138 71180 70910 64356504
Hot flush 18.23 9.94 100 71218 46135 64381279
Nasal discomfort 17.90 9.94 23 71295 4305 64423109
Poor quality device used 17.83 9.94 16 71302 1991 64425423
Victim of chemical submission 17.80 9.94 8 71310 292 64427122
Gastroenteritis viral 17.68 9.94 55 71263 19674 64407740
Feeling cold 17.64 9.94 62 71256 23616 64403798
Chemical burns of eye 17.57 9.94 6 71312 103 64427311
Rhabdomyolysis 17.54 9.94 48 71270 91678 64335736
Toxicity to various agents 17.37 9.94 290 71028 363223 64064191
Urinary tract infection 17.10 9.94 355 70963 231241 64196173
Cystic fibrosis 17.03 9.94 20 71298 3414 64424000
Pruritus 17.00 9.94 459 70859 311941 64115473
Rhinorrhoea 16.92 9.94 119 71199 59850 64367564
Sinus headache 16.84 9.94 22 71296 4185 64423229
Myelosuppression 16.84 9.94 3 71315 23827 64403587
Product prescribing error 16.81 9.94 9 71309 35260 64392154
Rash macular 16.78 9.94 61 71257 23624 64403790
Fatigue 16.59 9.94 998 70320 747732 63679682
Discomfort 16.47 9.94 41 71277 80837 64346577
Renal impairment 16.45 9.94 85 71233 134932 64292482
Mobility decreased 16.35 9.94 45 71273 85795 64341619
Gallbladder polyp 16.29 9.94 11 71307 901 64426513
Wound 16.18 9.94 38 71280 76439 64350975
Sinus disorder 15.96 9.94 48 71270 16860 64410554
Female genital tract fistula 15.78 9.94 17 71301 2641 64424773
Folliculitis 15.35 9.94 7 71311 30070 64397344
Laryngospasm 15.34 9.94 19 71299 3426 64423988
Condition aggravated 15.31 9.94 305 71013 372121 64055293
Blood pressure fluctuation 15.27 9.94 21 71297 51850 64375564
Vulvovaginal candidiasis 15.13 9.94 15 71303 2115 64425299
Paraesthesia oral 15.06 9.94 40 71278 13091 64414323
Tonsillar hypertrophy 14.90 9.94 12 71306 1289 64426125
Panic attack 14.87 9.94 54 71264 20899 64406515
Insomnia 14.85 9.94 304 71014 197532 64229882
Infusion site erythema 14.83 9.94 27 71291 6846 64420568
Rash 14.83 9.94 634 70684 457915 63969499
Lupus vulgaris 14.79 9.94 5 71313 83 64427331
Pancreatitis chronic 14.74 9.94 19 71299 3567 64423847
HIV associated nephropathy 14.66 9.94 7 71311 294 64427120
Hiatus hernia 14.65 9.94 52 71266 19905 64407509
Bicuspid aortic valve 14.59 9.94 4 71314 31 64427383
Hypoacusis 14.58 9.94 62 71256 25805 64401609
Tubulointerstitial nephritis 14.57 9.94 8 71310 30901 64396513
Genital ulceration 14.56 9.94 9 71309 634 64426780
Impaired healing 14.50 9.94 28 71290 60445 64366969
Prosopagnosia 14.48 9.94 4 71314 32 64427382
Death 14.41 9.94 415 70903 482290 63945124
Feeling hot 14.31 9.94 93 71225 45570 64381844
Oxygen saturation decreased 14.19 9.94 181 71137 106995 64320419
Bradycardia 14.07 9.94 75 71243 118144 64309270
Cellulitis 14.07 9.94 162 71156 93495 64333919
Biliary sepsis 13.92 9.94 12 71306 1416 64425998
Haemorrhoids 13.89 9.94 58 71260 23943 64403471
Pancytopenia 13.88 9.94 97 71221 143212 64284202
Biliary dyskinesia 13.78 9.94 15 71303 2357 64425057
Pulmonary fibrosis 13.70 9.94 8 71310 29870 64397544
Hyperpyrexia 13.66 9.94 22 71296 5055 64422359
Cholecystitis chronic 13.52 9.94 31 71287 9256 64418158
Pain in jaw 13.38 9.94 84 71234 40671 64386743
Swollen tongue 13.38 9.94 75 71243 34879 64392535
Exposure to toxic agent 13.04 9.94 24 71294 6135 64421279
Productive cough 13.03 9.94 131 71187 73072 64354342
Suffocation feeling 12.91 9.94 12 71306 1562 64425852
Walking aid user 12.71 9.94 24 71294 6257 64421157
Extrapyramidal disorder 12.70 9.94 3 71315 19549 64407865
Nail dystrophy 12.63 9.94 9 71309 804 64426610
Administration site extravasation 12.62 9.94 10 71308 1049 64426365
Depression 12.57 9.94 278 71040 183013 64244401
Toxic skin eruption 12.44 9.94 3 71315 19281 64408133
Neutropenia 12.44 9.94 350 70968 239274 64188140
Candida infection 12.42 9.94 68 71250 31351 64396063
Gastrointestinal disorder 12.37 9.94 54 71264 89655 64337759
HER2 positive breast cancer 12.37 9.94 6 71312 261 64427153
Tympanic membrane hyperaemia 12.24 9.94 3 71315 14 64427400
Dyspnoea exertional 12.20 9.94 130 71188 73600 64353814
Sinus operation 12.16 9.94 12 71306 1683 64425731
Red blood cell sedimentation rate increased 12.15 9.94 10 71308 31225 64396189
Muscle spasms 12.03 9.94 221 71097 140802 64286612
Product use issue 11.78 9.94 109 71209 151606 64275808
Loss of personal independence in daily activities 11.66 9.94 41 71277 72413 64355001
Eosinophilia 11.63 9.94 15 71303 38061 64389353
Haemodialysis complication 11.61 9.94 6 71312 299 64427115
Failure of child resistant product closure 11.59 9.94 4 71314 71 64427343
Accidental exposure to product by child 11.55 9.94 14 71304 2471 64424943
Altered state of consciousness 11.50 9.94 15 71303 37887 64389527
Tongue pruritus 11.48 9.94 7 71311 481 64426933
Oropharyngeal blistering 11.48 9.94 8 71310 690 64426724
Septic shock 11.41 9.94 69 71249 105368 64322046
Otitis media 11.35 9.94 21 71297 5392 64422022
Product complaint 11.34 9.94 34 71284 11920 64415494
Retinal detachment 10.93 9.94 26 71292 7950 64419464
Seasonal allergy 10.80 9.94 33 71285 11693 64415721
Mood swings 10.73 9.94 43 71275 17425 64409989
Agranulocytosis 10.73 9.94 16 71302 38213 64389201
Neutropenic infection 10.68 9.94 12 71306 1953 64425461
Toxic epidermal necrolysis 10.63 9.94 74 71244 37092 64390322
Onychalgia 10.53 9.94 8 71310 789 64426625
Vision blurred 10.50 9.94 149 71169 90167 64337247
Bronchopulmonary aspergillosis 10.45 9.94 4 71314 19081 64408333
Intentional self-injury 10.45 9.94 10 71308 29034 64398380
Vomiting 10.43 9.94 725 70593 550392 63877022
Hyperhidrosis 10.39 9.94 195 71123 124725 64302689
Anosmia 10.37 9.94 18 71300 4399 64423015
Vulvovaginal pain 10.20 9.94 11 71307 1711 64425703
Eye pruritus 10.18 9.94 34 71284 12625 64414789
Cyanosis 10.18 9.94 50 71268 22105 64405309
Product dose omission issue 9.97 9.94 284 71034 194463 64232951
Dyspepsia 9.95 9.94 134 71184 80178 64347236

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC R06AB04 RESPIRATORY SYSTEM
ANTIHISTAMINES FOR SYSTEMIC USE
ANTIHISTAMINES FOR SYSTEMIC USE
Substituted alkylamines
ATC R06AB54 RESPIRATORY SYSTEM
ANTIHISTAMINES FOR SYSTEMIC USE
ANTIHISTAMINES FOR SYSTEMIC USE
Substituted alkylamines
FDA MoA N0000000190 Histamine H1 Receptor Antagonists
FDA EPC N0000175587 Histamine-1 Receptor Antagonist
MeSH PA D018926 Anti-Allergic Agents
MeSH PA D000982 Antipruritics
MeSH PA D003879 Dermatologic Agents
MeSH PA D018494 Histamine Agents
MeSH PA D006633 Histamine Antagonists
MeSH PA D006634 Histamine H1 Antagonists
MeSH PA D018377 Neurotransmitter Agents
CHEBI has role CHEBI:35469 antidepressants
CHEBI has role CHEBI:37955 H1 receptor antagonists
CHEBI has role CHEBI:37956 antihistamines
CHEBI has role CHEBI:50857 anti-allergic drugs
CHEBI has role CHEBI:50949 SSRI
CHEBI has role CHEBI:59683 antipruritic drugs

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Dermatographic urticaria indication 7632005 DOID:743
Vasomotor rhinitis indication 8229003 DOID:4730
Allergic rhinitis indication 61582004
Nasal discharge indication 64531003
Nasal congestion indication 68235000
Sneezing indication 76067001
Common cold indication 82272006 DOID:10459
Urticaria indication 126485001
Influenza-like symptoms indication 315642008
Seasonal allergic rhinitis indication 367498001
Itching of skin indication 418363000
Allergic conjunctivitis indication 473460002 DOID:11204
Brain damage contraindication 2470005
Necrotizing enterocolitis in fetus OR newborn contraindication 2707005
Goiter contraindication 3716002 DOID:12176
Ocular hypertension contraindication 4210003 DOID:9282
Gastritis contraindication 4556007 DOID:4029
Tachyarrhythmia contraindication 6285003
Suicidal thoughts contraindication 6471006
Dependent drug abuse contraindication 6525002
Urinary tract obstruction contraindication 7163005 DOID:5200
Alcoholism contraindication 7200002
Alcohol withdrawal delirium contraindication 8635005
Peptic ulcer contraindication 13200003 DOID:750
Chronic obstructive lung disease contraindication 13645005 DOID:3083
Asthenia contraindication 13791008
Hyperkalemia contraindication 14140009
Severe chronic ulcerative colitis contraindication 14311001
Constipation contraindication 14760008 DOID:2089
Disorder of autonomic nervous system contraindication 15241006
Chronic disease of respiratory system contraindication 17097001
Mood swings contraindication 18963009
Hashimoto thyroiditis contraindication 21983002
Myocardial infarction contraindication 22298006 DOID:5844
Glaucoma contraindication 23986001 DOID:1686
Inflammatory bowel disease contraindication 24526004 DOID:0050589
Ventricular tachycardia contraindication 25569003
Acute tuberculosis contraindication 25629007
Alcohol intoxication contraindication 25702006
Shock contraindication 27942005
Toxic megacolon contraindication 28536002 DOID:1770
Atony of colon contraindication 29479008
Hypercapnia contraindication 29596007
Bronchitis contraindication 32398004 DOID:6132
Dehydration contraindication 34095006
Hyperthyroidism contraindication 34486009 DOID:7998
Acute hepatitis contraindication 37871000
Hypertensive disorder contraindication 38341003 DOID:10763
Hypovolemic shock contraindication 39419009
Disorder of gallbladder contraindication 39621005 DOID:0060262
Gastrointestinal ulcer contraindication 40845000
Hypothyroidism contraindication 40930008 DOID:1459
Complete trisomy 21 syndrome contraindication 41040004 DOID:14250
Body fluid retention contraindication 43498006
Conduction disorder of the heart contraindication 44808001
Low blood pressure contraindication 45007003
Achalasia of esophagus contraindication 45564002 DOID:9164
Chronic heart failure contraindication 48447003
Bradycardia contraindication 48867003
Disorder of cardiovascular system contraindication 49601007 DOID:1287
Acidosis contraindication 51387008
Gastrointestinal perforation contraindication 51875005
Vitamin K deficiency contraindication 52675005 DOID:11249
Nasal polyp contraindication 52756005
Coronary arteriosclerosis contraindication 53741008 DOID:3393
Paralytic ileus contraindication 55525008 DOID:8442
Peptic reflux disease contraindication 57643001
Acute nephropathy contraindication 58574008
Hepatic failure contraindication 59927004
Ulcerative colitis contraindication 64766004 DOID:8577
Blood coagulation disorder contraindication 64779008 DOID:1247
Arterial thrombosis contraindication 65198009
Drug AND/OR toxin-induced diarrhea contraindication 65979008
Substance abuse contraindication 66214007
Benign intracranial hypertension contraindication 68267002 DOID:11459
Psychotic disorder contraindication 69322001
Poisoning by acetaminophen contraindication 70273001
Agoraphobia contraindication 70691001 DOID:593
Arteriosclerotic vascular disease contraindication 72092001
Diabetes mellitus contraindication 73211009 DOID:9351
Factor II deficiency contraindication 73975000
Reye's syndrome contraindication 74351001 DOID:14525
Gastrointestinal hemorrhage contraindication 74474003
Urethral stricture contraindication 76618002
Thrombotic thrombocytopenic purpura contraindication 78129009 DOID:10772
Spastic paralysis contraindication 78403003
Disturbance of salivary secretion contraindication 78948009
Decreased respiratory function contraindication 80954004
Injury of head contraindication 82271004
Chronic idiopathic constipation contraindication 82934008
Cor pulmonale contraindication 83291003 DOID:8515
Hiatal hernia contraindication 84089009 DOID:12642
Epilepsy contraindication 84757009 DOID:1826
Pulmonary emphysema contraindication 87433001
Gout contraindication 90560007 DOID:13189
Kidney disease contraindication 90708001 DOID:557
Thyrotoxicosis contraindication 90739004 DOID:7997
Hemophilia contraindication 90935002
Myasthenia gravis contraindication 91637004 DOID:437
Dermatitis herpetiformis contraindication 111196000 DOID:8505
Anemia due to enzyme deficiency contraindication 111577008
Acute abdominal pain contraindication 116290004
Procedure on urinary system contraindication 118677009
Gastrointestinal obstruction contraindication 126765001
Neoplasm of brain contraindication 126952004 DOID:1319
von Willebrand disorder contraindication 128105004 DOID:12531
Seizure disorder contraindication 128613002
Autonomic dysreflexia contraindication 129618003
Bleeding contraindication 131148009
Drug-induced psychosis contraindication 191483003 DOID:1742
Obsessive-compulsive disorder contraindication 191736004 DOID:10933
Insomnia contraindication 193462001
Partial atrioventricular block contraindication 195039008
Acute pancreatitis contraindication 197456007 DOID:2913
Impaired renal function disorder contraindication 197663003
Coronary artery bypass graft contraindication 232717009
Myocardial dysfunction contraindication 233928007
Gastroesophageal reflux disease contraindication 235595009 DOID:8534
Disease of liver contraindication 235856003 DOID:409
Bladder outflow obstruction contraindication 236645006
Morbid obesity contraindication 238136002 DOID:11981
Hypocomplementemic urticarial vasculitis contraindication 239945009
Pyloric obstruction contraindication 244815007
Benign prostatic hyperplasia contraindication 266569009
Retention of urine contraindication 267064002
Anemia contraindication 271737000 DOID:2355
Drowsy contraindication 271782001
Exacerbation of asthma contraindication 281239006
Pregnancy, function contraindication 289908002
Lesion of brain contraindication 301766008
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Panic disorder contraindication 371631005 DOID:594
Coma contraindication 371632003
Primary adrenocortical insufficiency contraindication 373662000
Operation on gastrointestinal tract contraindication 386621005
Hypoxia contraindication 389086002
Angle-closure glaucoma contraindication 392291006 DOID:13550
Cardiovascular event risk contraindication 395112001
Pseudomembranous enterocolitis contraindication 397683000
Gastric ulcer contraindication 397825006 DOID:10808
Breastfeeding (mother) contraindication 413712001
Chronic lung disease contraindication 413839001
Chronic myocardial ischemia contraindication 413844008 DOID:3393
Disorder of coronary artery contraindication 414024009
Myocardial ischemia contraindication 414795007 DOID:3393
Myocardial infarction in recovery phase contraindication 418044006
Central nervous system depression contraindication 418072004
Ultrarapid metabolizer due to cytochrome p450 CYP2D6 variant contraindication 422681000
Fever greater than 100.4 Fahrenheit contraindication 426000000
Dysfunction of sphincter of Oddi contraindication 430887001
Hypertensive urgency contraindication 443482000
Acute erosive gastritis contraindication 444926003
Smokes tobacco daily contraindication 449868002
Acute exacerbation of asthma contraindication 708038006
Acute Thromboembolic Stroke contraindication




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.47 Basic
pKa2 4.14 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
8MG;54.3MG TUXARIN ER MAINPOINTE N206323 June 22, 2015 RX TABLET, EXTENDED RELEASE ORAL 9066942 Jan. 3, 2032 TREATMENT OF COUGH AND SYMPTOMS ASSOCIATED WITH UPPER RESPIRATORY ALLERGIES OR A COMMON COLD WITH CODEINE PHOSPHATE AND CHLORPHENIRAMINE MALEATE ORALLY ADMINISTERED EXTENDED RELEASE TABLETS

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Histamine H1 receptor GPCR ANTAGONIST Ki 8.15 WOMBAT-PK CHEMBL
Sodium-dependent serotonin transporter Transporter Kd 7.82 WOMBAT-PK
5-hydroxytryptamine receptor 2B GPCR Ki 5.17 PDSP
Histamine H4 receptor GPCR Ki 6.67 WOMBAT-PK
Cytochrome P450 2D6 Enzyme Ki 4.97 WOMBAT-PK
Sodium channel alpha subunits; brain (Types I, II, III) Ion channel IC50 5 CHEMBL
Lethal(3)malignant brain tumor-like protein 1 Unclassified IC50 4.39 CHEMBL
Lethal(3)malignant brain tumor-like protein 3 Unclassified IC50 4.38 CHEMBL
MBT domain-containing protein 1 Unclassified IC50 4.47 CHEMBL
Sodium-dependent noradrenaline transporter Transporter Kd 5.84 SCIENTIFIC LITERATURE
Potassium voltage-gated channel subfamily H member 2 Ion channel IC50 5.96 CHEMBL
Sodium-dependent dopamine transporter Transporter Kd 5.98 SCIENTIFIC LITERATURE
Histamine H1 receptor GPCR IC50 8.06 CHEMBL
Histamine H1 receptor GPCR Ki 8.70 CHEMBL
Chloroquine resistance transporter Transporter IC50 4.27 CHEMBL

External reference:

IDSource
4017865 VUID
N0000146218 NUI
D00665 KEGG_DRUG
113-92-8 SECONDARY_CAS_RN
1405-56-7 SECONDARY_CAS_RN
142429 RXNORM
4017864 VANDF
4017865 VANDF
4018446 VANDF
4019408 VANDF
C0008281 UMLSCUI
CHEBI:52010 CHEBI
CHEMBL505 ChEMBL_ID
CHEMBL1659 ChEMBL_ID
DB01114 DRUGBANK_ID
6976 IUPHAR_LIGAND_ID
2725 PUBCHEM_CID
32347 MMSL
32562 MMSL
3966 MMSL
4425 MMSL
4426 MMSL
4427 MMSL
4751 MMSL
93262 MMSL
d00191 MMSL
003391 NDDF
003392 NDDF
004430 NDDF
004431 NDDF
372914003 SNOMEDCT_US
438256006 SNOMEDCT_US
85737002 SNOMEDCT_US
9944001 SNOMEDCT_US
D002744 MESH_DESCRIPTOR_UI
CHEMBL1201659 ChEMBL_ID
104 INN_ID
3U6IO1965U UNII

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Childrens Robitussin Nighttime Cough Long-Acting DM HUMAN OTC DRUG LABEL 2 0031-8692 SOLUTION 2 mg ORAL OTC monograph final 17 sections
Childrens Robitussin Nighttime Cough Long-Acting DM HUMAN OTC DRUG LABEL 2 0031-8692 SOLUTION 2 mg ORAL OTC monograph final 17 sections
CHILDRENS ROBITUSSIN COUGH AND COLD LONG-ACTING HUMAN OTC DRUG LABEL 2 0031-8693 LIQUID 1 mg ORAL OTC monograph final 17 sections
TriaminicMulti-Symptom Fever and Cold HUMAN OTC DRUG LABEL 4 0067-8116 SUSPENSION 1 mg ORAL OTC monograph final 15 sections
good sense cold HUMAN OTC DRUG LABEL 4 0113-0903 SUSPENSION 1 mg ORAL OTC monograph final 15 sections
Allergy HUMAN OTC DRUG LABEL 3 0113-2476 TABLET 2 mg ORAL OTC monograph final 15 sections
basic care childrens cold plus flu HUMAN OTC DRUG LABEL 4 0113-7223 SUSPENSION 1 mg ORAL OTC monograph final 15 sections
FLONASEHeadache and Allergy Relief HUMAN OTC DRUG LABEL 3 0135-0578 TABLET 2 mg ORAL OTC monograph final 17 sections
TussiCaps HUMAN PRESCRIPTION DRUG LABEL 2 0187-0054 CAPSULE, EXTENDED RELEASE 4 mg ORAL ANDA 24 sections
TussiCaps HUMAN PRESCRIPTION DRUG LABEL 2 0187-0108 CAPSULE, EXTENDED RELEASE 8 mg ORAL ANDA 24 sections
Alka-Seltzer Plus Severe Cold PowerFast FizzOrange Zest HUMAN OTC DRUG LABEL 3 0280-0020 TABLET, EFFERVESCENT 2 mg ORAL OTC monograph final 17 sections
Alka-Seltzer Plus Severe Cold and Flu PowerFast Fizz HUMAN OTC DRUG LABEL 4 0280-0022 TABLET, EFFERVESCENT 2 mg ORAL OTC monograph final 16 sections
Alka-Seltzer Plus Severe Cold and Flu PowerFast Fizz HUMAN OTC DRUG LABEL 4 0280-0022 TABLET, EFFERVESCENT 2 mg ORAL OTC monograph final 16 sections
Alka-Seltzer Plus Severe Cold and Cough PowerFast Fizz HUMAN OTC DRUG LABEL 4 0280-0023 TABLET, EFFERVESCENT 2 mg ORAL OTC monograph final 16 sections
Alka-Seltzer Plus Severe Cold and Cough PowerFast Fizz HUMAN OTC DRUG LABEL 4 0280-0023 TABLET, EFFERVESCENT 2 mg ORAL OTC monograph final 16 sections
ANTIFLU HUMAN OTC DRUG LABEL 3 0280-0044 TABLET, COATED 2 mg ORAL Export only 2 sections
Antiflupowder HUMAN OTC DRUG LABEL 3 0280-0045 POWDER, FOR SOLUTION 4 mg ORAL Export only 1 sections
Antiflu Kids HUMAN OTC DRUG LABEL 3 0280-0046 POWDER, FOR SOLUTION 1 mg ORAL Export only 2 sections
Alka-Seltzer Plus Maximum Strength Sinus Congestion and Pain PowerFast Fizz HUMAN OTC DRUG LABEL 4 0280-0055 TABLET, EFFERVESCENT 2 mg ORAL OTC monograph final 15 sections
Alka-Seltzer Plus Cold Sparkling Original PowerFast Fizz HUMAN OTC DRUG LABEL 3 0280-0060 TABLET, EFFERVESCENT 2 mg ORAL OTC monograph final 15 sections
Alka-Seltzer Plus Severe Cold and Flu PowerFast Fizz HUMAN OTC DRUG LABEL 4 0280-0088 TABLET, EFFERVESCENT 2 mg ORAL OTC monograph final 16 sections
Alka-Seltzer Plus Maximum Strength Cold and Cough Power Max Gels HUMAN OTC DRUG LABEL 4 0280-0092 CAPSULE, LIQUID FILLED 2 mg ORAL OTC monograph final 17 sections
Alka-Seltzer Plus Cold Medicine Sparkling Original HUMAN OTC DRUG LABEL 3 0280-1400 TABLET, EFFERVESCENT 2 mg ORAL OTC monograph not final 17 sections
Alka-Seltzer Plus Cold Orange Zest HUMAN OTC DRUG LABEL 3 0280-1510 TABLET, EFFERVESCENT 2 mg ORAL OTC monograph final 17 sections
Alka-Seltzer Plus Cold Sparkling Original HUMAN OTC DRUG LABEL 3 0280-1520 TABLET, EFFERVESCENT 2 mg ORAL OTC monograph final 17 sections
Alka-Seltzer Plus Cold and Cough HUMAN OTC DRUG LABEL 4 0280-1555 TABLET, EFFERVESCENT 2 mg ORAL OTC monograph final 16 sections
Alka-Seltzer Plus Severe Cold and Flu HUMAN OTC DRUG LABEL 4 0280-1560 TABLET, EFFERVESCENT 2 mg ORAL OTC monograph final 17 sections
Alka-Seltzer Plus Maximum Strength Cold and Cough HUMAN OTC DRUG LABEL 4 0280-1570 CAPSULE, LIQUID FILLED 2 mg ORAL OTC monograph final 17 sections
Childrens Plus Multi Symptom Cold HUMAN OTC DRUG LABEL 4 0363-0034 SUSPENSION 1 mg ORAL OTC MONOGRAPH FINAL 15 sections
Childrens Plus Multi Symptom Cold HUMAN OTC DRUG LABEL 4 0363-0034 SUSPENSION 1 mg ORAL OTC MONOGRAPH FINAL 15 sections